Biostar Pharmaceuticals, Inc.
BSPM · OTC
9/30/2017 | 6/30/2017 | 3/31/2017 | 12/31/2016 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.07 | -0.02 | 0.01 | -0.00 |
| FCF Yield | -0.04% | 105.73% | 5.27% | 53.41% |
| EV / EBITDA | 23.80 | -6.09 | -11.85 | 1.52 |
| Quality | ||||
| ROIC | -1.49% | -4.04% | -2.70% | 8.48% |
| Gross Margin | 0.00% | 0.00% | 0.00% | -11.56% |
| Cash Conversion Ratio | 0.01 | -3.25 | -0.32 | 1.18 |
| Growth | ||||
| Revenue 3-Year CAGR | -79.99% | -73.22% | -69.38% | -66.14% |
| Free Cash Flow Growth | -100.03% | 1,228.38% | -91.98% | 617.88% |
| Safety | ||||
| Net Debt / EBITDA | 9.28 | -2.00 | -2.77 | 0.34 |
| Interest Coverage | -12.14 | -33.29 | -22.75 | 94.86 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 1.81 | 2.13 |
| Cash Conversion Cycle | 0.00 | 0.00 | -714.28 | 1,261.93 |